GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shijiazhuang Yiling Pharmaceutical Co Ltd (SZSE:002603) » Definitions » Additional Paid-In Capital

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Additional Paid-In Capital : ¥0 Mil(As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Shijiazhuang Yiling Pharmaceutical Co Additional Paid-In Capital?


Shijiazhuang Yiling Pharmaceutical Co's quarterly additional paid-in capital increased from Sep. 2023 (¥0 Mil) to Dec. 2023 (¥2,283 Mil) but then stayed the same from Dec. 2023 (¥2,283 Mil) to Mar. 2024 (¥0 Mil).

Shijiazhuang Yiling Pharmaceutical Co's annual additional paid-in capital stayed the same from Dec. 2021 (¥2,283 Mil) to Dec. 2022 (¥2,283 Mil) and stayed the same from Dec. 2022 (¥2,283 Mil) to Dec. 2023 (¥2,283 Mil).


Shijiazhuang Yiling Pharmaceutical Co Additional Paid-In Capital Historical Data

The historical data trend for Shijiazhuang Yiling Pharmaceutical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shijiazhuang Yiling Pharmaceutical Co Additional Paid-In Capital Chart

Shijiazhuang Yiling Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,872.46 2,872.46 2,283.31 2,283.31 2,283.31

Shijiazhuang Yiling Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2,283.31 - 2,283.31 -

Shijiazhuang Yiling Pharmaceutical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Shijiazhuang Yiling Pharmaceutical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Shijiazhuang Yiling Pharmaceutical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Business Description

Traded in Other Exchanges
N/A
Address
No. 7 Tianfu street, Biology and medicine industrial base, Huangcun town, Daxing district, Beijing, CHN
Shijiazhuang Yiling Pharmaceutical Co Ltd is a China-based company engages in the pharmaceutical manufacturing. The company is principally engaged in the research, development, manufacturing, and sales of traditional Chinese pharmaceutical products, especially in the fields of cardiovascular and cerebrovascular diseases, respiratory diseases, tumor, diabetes and related complications. Its products include innovative drug series, chemical drugs, Chinese medicine series, and health products.
Executives
Zhang Qiu Lian Directors, executives
Han Yue Zhi Executives
Zhao Shao Hua Executives
Wang Wei Executives
Gao Xue Dong Supervisors
Wu Yi Ling Director
Gao Xiu Qiang Executives
Wu Xiang Jun Directors, executives
Guo Shuang Geng Director
Wang Hua Securities Affairs Representative
Dai Feng Xiang Directors, executives
Liu Gen Wu Supervisors
Wang Wei Ping Directors, executives
Xu Wei Dong Director
Wu Rui Directors, executives

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Headlines

No Headlines